Dual targeting of Bcl-2 and VEGF

A potential strategy to improve therapy for prostate cancer

Satoshi Anai, Noboru Sakamoto, Yoshihisa Sakai, Motoyoshi Tanaka, Stacy Porvasnik, Cydney Urbanek, Wengang Cao, Steven Goodison, Charles J. Rosser

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

We previously demonstrated that Bcl-2 overexpression stimulates angiogenesis in PC-3 human prostate cancer cells, thus giving these tumors a growth advantage. To further elucidate the relationship between Bcl-2 and vascular endothelial growth factor (VEGF) in PC-3-Bcl-2 cells, tumorigenicity and angiogenesis were evaluated in our in vitro and in vivo model treated with antisense Bcl-2 oligodeoxynucleotide (ASO) and bevacizumab. In vitro and in vivo angiogenesis assays, as well as a xenograft tumor model of the human prostate cancer cell line PC-3-Bcl-2, were subjected to ASO alone, bevacizumab alone, or the combination of ASO and bevacizumab. Protein-based assays (e.g., immunohistochemical staining and enzyme-linked immunosorbent assay [ELISA]) were utilized to detect molecular changes. Interestingly, targeting Bcl-2 with ASO resulted in the inhibition of in vitro tube formation and inhibition of angiogenesis in Matrigel plugs similar to treatment with bevacizumab. In our PC-3-Bcl-2 xenograft model, ASO alone resulted in 41% reduction in tumor size, bevacizumab alone resulted in a 50% reduction in tumor size, whereas the combination of ASO with bevacizumab was associated with >95% reduction in tumor volume. Reduction in tumor size in all groups was associated with reduction in Bcl-2 and VEGF expression, induction of apoptosis, and inhibition of angiogenesis and its associated chemokine production. These findings confirm that Bcl-2 is a pivotal target for cancer therapy and thus, further study of this novel combination of Bcl-2 reduction and angiogenic targeting in human tumors is warranted.

Original languageEnglish (US)
Pages (from-to)421-429
Number of pages9
JournalUrologic Oncology: Seminars and Original Investigations
Volume29
Issue number4
DOIs
StatePublished - Jul 1 2011
Externally publishedYes

Fingerprint

Vascular Endothelial Growth Factor A
Prostatic Neoplasms
Neoplasms
Heterografts
Therapeutics
Tumor Burden
Chemokines
Bevacizumab
oblimersen
Enzyme-Linked Immunosorbent Assay
Apoptosis
Staining and Labeling
Cell Line
Growth
In Vitro Techniques
Proteins

Keywords

  • Angiogenesis
  • Bcl-2
  • Therapeutic
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Dual targeting of Bcl-2 and VEGF : A potential strategy to improve therapy for prostate cancer. / Anai, Satoshi; Sakamoto, Noboru; Sakai, Yoshihisa; Tanaka, Motoyoshi; Porvasnik, Stacy; Urbanek, Cydney; Cao, Wengang; Goodison, Steven; Rosser, Charles J.

In: Urologic Oncology: Seminars and Original Investigations, Vol. 29, No. 4, 01.07.2011, p. 421-429.

Research output: Contribution to journalArticle

Anai, Satoshi ; Sakamoto, Noboru ; Sakai, Yoshihisa ; Tanaka, Motoyoshi ; Porvasnik, Stacy ; Urbanek, Cydney ; Cao, Wengang ; Goodison, Steven ; Rosser, Charles J. / Dual targeting of Bcl-2 and VEGF : A potential strategy to improve therapy for prostate cancer. In: Urologic Oncology: Seminars and Original Investigations. 2011 ; Vol. 29, No. 4. pp. 421-429.
@article{af56b45afadf499995d624ffbf35eeb5,
title = "Dual targeting of Bcl-2 and VEGF: A potential strategy to improve therapy for prostate cancer",
abstract = "We previously demonstrated that Bcl-2 overexpression stimulates angiogenesis in PC-3 human prostate cancer cells, thus giving these tumors a growth advantage. To further elucidate the relationship between Bcl-2 and vascular endothelial growth factor (VEGF) in PC-3-Bcl-2 cells, tumorigenicity and angiogenesis were evaluated in our in vitro and in vivo model treated with antisense Bcl-2 oligodeoxynucleotide (ASO) and bevacizumab. In vitro and in vivo angiogenesis assays, as well as a xenograft tumor model of the human prostate cancer cell line PC-3-Bcl-2, were subjected to ASO alone, bevacizumab alone, or the combination of ASO and bevacizumab. Protein-based assays (e.g., immunohistochemical staining and enzyme-linked immunosorbent assay [ELISA]) were utilized to detect molecular changes. Interestingly, targeting Bcl-2 with ASO resulted in the inhibition of in vitro tube formation and inhibition of angiogenesis in Matrigel plugs similar to treatment with bevacizumab. In our PC-3-Bcl-2 xenograft model, ASO alone resulted in 41{\%} reduction in tumor size, bevacizumab alone resulted in a 50{\%} reduction in tumor size, whereas the combination of ASO with bevacizumab was associated with >95{\%} reduction in tumor volume. Reduction in tumor size in all groups was associated with reduction in Bcl-2 and VEGF expression, induction of apoptosis, and inhibition of angiogenesis and its associated chemokine production. These findings confirm that Bcl-2 is a pivotal target for cancer therapy and thus, further study of this novel combination of Bcl-2 reduction and angiogenic targeting in human tumors is warranted.",
keywords = "Angiogenesis, Bcl-2, Therapeutic, Vascular endothelial growth factor",
author = "Satoshi Anai and Noboru Sakamoto and Yoshihisa Sakai and Motoyoshi Tanaka and Stacy Porvasnik and Cydney Urbanek and Wengang Cao and Steven Goodison and Rosser, {Charles J.}",
year = "2011",
month = "7",
day = "1",
doi = "10.1016/j.urolonc.2009.04.009",
language = "English (US)",
volume = "29",
pages = "421--429",
journal = "Urologic Oncology",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Dual targeting of Bcl-2 and VEGF

T2 - A potential strategy to improve therapy for prostate cancer

AU - Anai, Satoshi

AU - Sakamoto, Noboru

AU - Sakai, Yoshihisa

AU - Tanaka, Motoyoshi

AU - Porvasnik, Stacy

AU - Urbanek, Cydney

AU - Cao, Wengang

AU - Goodison, Steven

AU - Rosser, Charles J.

PY - 2011/7/1

Y1 - 2011/7/1

N2 - We previously demonstrated that Bcl-2 overexpression stimulates angiogenesis in PC-3 human prostate cancer cells, thus giving these tumors a growth advantage. To further elucidate the relationship between Bcl-2 and vascular endothelial growth factor (VEGF) in PC-3-Bcl-2 cells, tumorigenicity and angiogenesis were evaluated in our in vitro and in vivo model treated with antisense Bcl-2 oligodeoxynucleotide (ASO) and bevacizumab. In vitro and in vivo angiogenesis assays, as well as a xenograft tumor model of the human prostate cancer cell line PC-3-Bcl-2, were subjected to ASO alone, bevacizumab alone, or the combination of ASO and bevacizumab. Protein-based assays (e.g., immunohistochemical staining and enzyme-linked immunosorbent assay [ELISA]) were utilized to detect molecular changes. Interestingly, targeting Bcl-2 with ASO resulted in the inhibition of in vitro tube formation and inhibition of angiogenesis in Matrigel plugs similar to treatment with bevacizumab. In our PC-3-Bcl-2 xenograft model, ASO alone resulted in 41% reduction in tumor size, bevacizumab alone resulted in a 50% reduction in tumor size, whereas the combination of ASO with bevacizumab was associated with >95% reduction in tumor volume. Reduction in tumor size in all groups was associated with reduction in Bcl-2 and VEGF expression, induction of apoptosis, and inhibition of angiogenesis and its associated chemokine production. These findings confirm that Bcl-2 is a pivotal target for cancer therapy and thus, further study of this novel combination of Bcl-2 reduction and angiogenic targeting in human tumors is warranted.

AB - We previously demonstrated that Bcl-2 overexpression stimulates angiogenesis in PC-3 human prostate cancer cells, thus giving these tumors a growth advantage. To further elucidate the relationship between Bcl-2 and vascular endothelial growth factor (VEGF) in PC-3-Bcl-2 cells, tumorigenicity and angiogenesis were evaluated in our in vitro and in vivo model treated with antisense Bcl-2 oligodeoxynucleotide (ASO) and bevacizumab. In vitro and in vivo angiogenesis assays, as well as a xenograft tumor model of the human prostate cancer cell line PC-3-Bcl-2, were subjected to ASO alone, bevacizumab alone, or the combination of ASO and bevacizumab. Protein-based assays (e.g., immunohistochemical staining and enzyme-linked immunosorbent assay [ELISA]) were utilized to detect molecular changes. Interestingly, targeting Bcl-2 with ASO resulted in the inhibition of in vitro tube formation and inhibition of angiogenesis in Matrigel plugs similar to treatment with bevacizumab. In our PC-3-Bcl-2 xenograft model, ASO alone resulted in 41% reduction in tumor size, bevacizumab alone resulted in a 50% reduction in tumor size, whereas the combination of ASO with bevacizumab was associated with >95% reduction in tumor volume. Reduction in tumor size in all groups was associated with reduction in Bcl-2 and VEGF expression, induction of apoptosis, and inhibition of angiogenesis and its associated chemokine production. These findings confirm that Bcl-2 is a pivotal target for cancer therapy and thus, further study of this novel combination of Bcl-2 reduction and angiogenic targeting in human tumors is warranted.

KW - Angiogenesis

KW - Bcl-2

KW - Therapeutic

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=79959879734&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959879734&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2009.04.009

DO - 10.1016/j.urolonc.2009.04.009

M3 - Article

VL - 29

SP - 421

EP - 429

JO - Urologic Oncology

JF - Urologic Oncology

SN - 1078-1439

IS - 4

ER -